O
Om Silakari
Researcher at Punjabi University
Publications - 107
Citations - 1141
Om Silakari is an academic researcher from Punjabi University. The author has contributed to research in topics: Pharmacophore & Virtual screening. The author has an hindex of 15, co-authored 106 publications receiving 815 citations.
Papers
More filters
Journal ArticleDOI
Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy.
Nisha Mehta,Maninder Kaur,Manjinder Singh,Sukhvir Chand,Bhawna Vyas,Pragati Silakari,Malkeet Singh Bahia,Om Silakari +7 more
TL;DR: Various aspects of P2X₇ receptors are explored including therapeutic potential, and recent discoveries and developments of P 2X⁇ receptor antagonists to serve as novel therapeutic agents to combat various inflammatory conditions.
Journal ArticleDOI
The Current Status of O-Heterocycles: A Synthetic and Medicinal Overview
Pankaj Kumar Singh,Om Silakari +1 more
TL;DR: A critical analysis of the synthesis and medicinal attributes of O‐heterocycles, such as pyrones, oxazolones, furanones, oxetanes, oxezolidinones, and dioxolonones, reported in the last five years, underlining the need for and the advantages guiding researchers toward them.
Journal ArticleDOI
Exploration of the therapeutic aspects of Lck: A kinase target in inflammatory mediated pathological conditions.
TL;DR: Evidence and information are provided establishing Lck as one of the therapeutic targets in various inflammation mediated pathophysiological conditions.
Journal ArticleDOI
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications
TL;DR: The present review focuses on the recent developments in the area of CSF-1R/c-FMS inhibitors with emphasis on crystal structure, mechanism of action and various therapeutic implications in which c-F MS plays a pivotal role.
Journal ArticleDOI
Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET
Pankaj Kumar Singh,Om Silakari +1 more
TL;DR: This work is one of the earliest report of compounds having significant dual inhibitory potential against secondary acquired EGFR and cMET, with IC50 values in nanomolar range.